Targeted Treatments for PALB2-Related Cancers

While a PALB2 mutation is a risk factor, it also provides your medical team with a specialized “blueprint” for treatment if cancer ever develops. This information is not for prevention, but it serves as a clue for active treatment. Because your mutation affects how your cells repair themselves, it creates a specific vulnerability in cancer cells that certain drugs can potentially exploit ^[1][2].

Understanding Your Repair Toolkit (HRD)

To understand how these treatments work, you first need to understand Homologous Recombination Deficiency (HRD).

As discussed on earlier pages, PALB2 is a key part of your DNA repair crew. In a healthy cell, the PALB2 protein helps bridge BRCA1 and BRCA2 to fix serious breaks in DNA ^[1]. When a cancer tumor develops in someone with a PALB2 mutation, the tumor sometimes loses the second, working copy of the gene ^[3].

This leaves the cancer cell with HRD—essentially a broken toolkit for DNA repair ^[3]. Because the cancer cell cannot fix itself normally, it may be more sensitive to certain types of therapy that cause DNA damage ^[2][4]. Your oncologist may perform somatic testing (testing the tumor itself) to see if it shows signs of this loss of heterozygosity, though these tests are not perfect predictors of treatment success.

Targeted Therapy: PARP Inhibitors

PARP inhibitors are a class of targeted drugs designed to block cancer cells with HRD from repairing themselves. These drugs include:

• Olaparib
• Talazoparib
• Rucaparib

How they work: Your cells have several ways to fix DNA. When the PALB2 pathway is broken, the cell relies on a backup system that uses an enzyme called PARP ^[2]. A PARP inhibitor blocks this backup system. For a PALB2 cancer cell, losing both the primary and backup systems leads to overwhelming DNA damage, causing the cell to die ^[2].

Clinical Evidence and Limitations:
Evidence for PARP inhibitors in PALB2-mutated cancers comes primarily from small, nonrandomized clinical trials, often in advanced settings.

• Breast Cancer: In a small phase II study of patients with metastatic breast cancer and a PALB2 mutation, there was an 82% objective response rate to olaparib ^[5]. Talazoparib has also shown promise in pilot studies ^[6].
• Pancreatic Cancer: For advanced pancreatic cancer, rucaparib has been used as a “maintenance” therapy for patients whose cancer was pre-treated by chemotherapy. In one small cohort, 50% of PALB2 carriers responded ^[7].

It is important to know that response rates from small cohorts do not predict an individual outcome. Furthermore, a PALB2 result is not equivalent to an automatic FDA-approved PARP indication; regulatory approvals vary by cancer type, biomarker, prior therapy, and jurisdiction. Some uses may be off-label or part of clinical trials.

Platinum-Based Chemotherapy

For PALB2 carriers, platinum-based chemotherapies (such as cisplatin and carboplatin) can be an important part of treatment.

These drugs work by physically cross-linking DNA strands, creating damage that requires the PALB2/BRCA repair crew to fix ^[4]. Because HRD cancer cells lack this crew, they are often sensitive to platinum drugs ^[2]. In pancreatic cancer, one small study found a 65% response rate to a platinum-based regimen in patients with PALB2 or BRCA mutations ^[8].

Weighing Risks and Side Effects

While these treatments can be effective, they carry significant side effects. Both PARP inhibitors and platinum chemotherapy can affect healthy cells, leading to substantial toxicity.

Common serious side effects include:

• Cytopenias (low white blood cells, red blood cells, or platelets).
• Severe fatigue and nausea.
• Neuropathy or kidney effects (specifically with platinum drugs).
• A rare but serious risk of therapy-related myelodysplastic syndrome or acute myeloid leukemia (MDS/AML).

Additionally, cancers can develop resistance to these treatments over time. The choice to use them depends heavily on your specific tumor type, stage, receptor status, comorbidities, and personal preferences, guided by an expert oncology team.